logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

Johnson & Johnson COVID-19 Vaccine Voting Tomorrow with Expected Approval on Saturday

Johnson & Johnson COVID-19 Vaccine According to a new analysis posted online by the FDA, the Johnson & Johnson ( JNJ ) vaccine is providing strong protection against severe disease and death related to COVID-19 infection. The vaccine may reduce...

Read More

February 25, 2021

0

CRISPR Therapeutics and Sisters

CRISPR, Intellia and Editas CRISPR Therapeutics ( CRSP ) announced revenues of Q4 2019 that beat analysts’ expectations. Based on the good news the stock market’s technicians contributed to boosting the stock’s price enabling the stock to recuperate a large...

Read More

February 13, 2020

0

Prilenia Therapeutics' Pridopidine Product for Huntington's and Lou Gehrig's Diseases Could be Promising

Prilenia Therapeutics Prilenia Therapeutics is a clinical-stage biotech company. The firm’s leader, Michael Hayden, MD, PhD., is a world-renowned scientist in Huntington's Disease ( HD ) research. Dr. Hayden was the President of Global R&D and Chief Scientific Officer at...

Read More

May 25, 2021

0

Biotech Stocks Expected to Outperform in Today's Tumbling Market

Gilead and Moderna Stocks Will Outperform Today As stated in Prohost Letter #439 Gilead ( GILD ) investigational product remdesivir has offered hope towards treating infected people with COVID-19 . Regarding the possibility of rapidly designing, creating and developing a...

Read More

February 24, 2020

0

Gilead Sciences To Acquire Forty Seven at $95.50 a Share in Cash

Gilead Sciences to Acquire Forty Seven Gilead Sciences ( GILD ) and  Forty Seven ( FTSV ) announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Forty Seven for $95.50 per share in cash ....

Read More

March 2, 2020

0

Aveo Oncology: The FDA Approved FOTIVDA for Adults with Relapsed or Refractory Advanced RCC

Aveo Oncology Received FDA Approval for FOTIVDA for Advanced RCC Aveo Oncology ( AVEO ) drug FOTIVDA is an oral, next-generation vascular endothelial growth factor ( VEGF ) tyrosine kinase inhibitor ( TKI ). It is a potent, selective inhibitor...

Read More

March 11, 2021

0

Immutep Ltd: Evaluating the Safety and Efficacy of Eftilagimod Alpha in Combination with Merck's KEYTRUDA

Immutep Ltd and Merck Announce Second Clinical Trial Collaboration Immutep ( IMMP ) develops novel immunotherapy treatments for cancer, infectious disease and autoimmune diseases. Today, Immutep announced a second clinical trial collaboration and supply agreement with Merck & Co (...

Read More

March 16, 2021

0

Its All About Coronavirus

Coronavirus: The Possible Treatments While Moderna’s ( MRNA ) vaccine is being tested and its stock price continued to rise in the worst market performance day; other companies demonstrated readiness to bring their vaccines against the life-threatening virus into human...

Read More

March 19, 2020

0

Novartis Announced Positive Results of Phase 3 Study Using 177Lu-PSMA-617 in Advanced Prostate Cancer Patients

Novartis Positive Results for Radioligand Therapy, 177Lu-PSMA-617, for mCRPC Novartis ( NVS ) reported the first interpretable results of evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (...

Read More

March 24, 2021

0

Intellia Therapeutics' Important Current Presentations

Current Presentations from Intellia Therapeutics  Intellia Therapeutics ( NTLA ) is presenting the first preclinical data set on its novel cytosine deaminase base editor technology at the seventh Cold Spring Harbor Laboratory ( CSHL ) virtual scientific meeting on Nucleic Acid Therapies....

Read More

March 25, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 92
  • 93
  • 94
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy